Eli Lilly's weight-loss, diabetes drug shortage is resolved, says US FDA

Q: How long will it take to read this news story?

The story "Eli Lilly&#039;s weight-loss, diabetes drug shortage is resolved, says US FDA" has 676 words across 25 sentences, which will take approximately 3 - 6 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "Eli Lilly&#039;s weight-loss, diabetes drug shortage is resolved, says US FDA" was covered 18 hours ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 312 news stories per day. It's most recent story was published 3 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #24565202</li><li>URL: https://beamstart.com/news/eli-lillys-weight-loss-diabetes-17346707377787</li></ul>

Business Standard Logo Business Standard 18h ago

Eli Lilly's weight-loss, diabetes drug shortage is resolved, says US FDA - Business Standard

Quick Summary:

They said that if the Outsourcing Facilities Association files a motion asking the court to block the FDA's decision within the next two weeks, the agency has agreed not to take any enforcement action while the court considers it.

The Outsourcing Facilities Association claimed the FDA had made its decision based on Lilly's claims it could meet demand for the drugs, without giving the public a chance to weigh in.

The lawsuit was put on hold days later after the FDA agreed to reconsider the decision, allowing sales of compounded versions to continue in the meantime.